Kezar Life Sciences, Inc.

NasdaqCM:KZR Stock Report

Market Cap: US$54.2m

Kezar Life Sciences Future Growth

Future criteria checks 2/6

Kezar Life Sciences is forecast to grow earnings and revenue by 7.4% and 48% per annum respectively while EPS is expected to grow by 12.8% per annum.

Key information

7.4%

Earnings growth rate

12.8%

EPS growth rate

Biotechs earnings growth28.5%
Revenue growth rate48.0%
Future return on equityn/a
Analyst coverage

Good

Last updated14 Nov 2024

Recent future growth updates

Recent updates

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Oct 03

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Aug 15
Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Aug 11

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Jul 27

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Jul 11

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Jan 03
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Apr 05
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Mar 01
Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Jan 25
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Dec 21
Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

Dec 14

Earnings and Revenue Growth Forecasts

NasdaqCM:KZR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-64N/A-264
12/31/20253-69N/A-386
12/31/2024N/A-83N/A-695
9/30/2024N/A-96-76-76N/A
6/30/20247-99-79-79N/A
3/31/20247-101-85-84N/A
12/31/20237-102-83-82N/A
9/30/20237-88-81-79N/A
6/30/2023N/A-83-77-75N/A
3/31/2023N/A-74-68-66N/A
12/31/2022N/A-68-60-59N/A
9/30/2022N/A-64-56-54N/A
6/30/2022N/A-61-49-48N/A
3/31/2022N/A-58-48-47N/A
12/31/2021N/A-55-43-42N/A
9/30/2021N/A-51-41-41N/A
6/30/2021N/A-48-40-40N/A
3/31/2021N/A-45-37-37N/A
12/31/2020N/A-42-37-37N/A
9/30/2020N/A-40-35-35N/A
6/30/2020N/A-38-34-34N/A
3/31/2020N/A-37-32-31N/A
12/31/2019N/A-35-30-30N/A
9/30/2019N/A-31-29-28N/A
6/30/2019N/A-28-25-24N/A
3/31/2019N/A-26-25-24N/A
12/31/2018N/A-23-22-21N/A
9/30/2018N/A-20-18-17N/A
6/30/2018N/A-16N/A-15N/A
3/31/2018N/A-11N/A-10N/A
12/31/2017N/A-9N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KZR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KZR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KZR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KZR's revenue (48% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: KZR's revenue (48% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KZR's Return on Equity is forecast to be high in 3 years time


Discover growth companies